Tissue Microarray Is a Reliable Tool for the Evaluation of HER2 Amplification in Breast Cancer

Furrer, Daniela; Jacob, Simon; Caron, Catherine; Sanschagrin, François; Provencher, Louise; Diorio, Caroline

doi:10.21873/anticanres.11017

Cited by 10 publications

(14 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The concordance results observed in those studies were evaluated using the 2007 ASCO/CAP scoring criteria (6). When we analyzed our data 18 were IHC 2+ and one was IHC 3+) and kappa value was 0.66), within the concordance range reported in the above mentioned studies. Among the 431 cases considered FISH non-amplified, one (0.2%) was evaluated as positive for protein expression.…”

Section: Discussionsupporting

confidence: 78%

“…Average HER2 status by IHC and FISH on random TMA sections were available for 99 cases out of the 116 selected cases (85.3%). In order to evaluate the agreement between the two methods, positive, negative and overall concordance were calculated as previously published (18) following the recommendation of the 2013 ASCO/CAP guidelines (5). The level of agreement was also measured using the Cohen's kappa test (agreement adjusted by chance).…”

Section: Discussionmentioning

confidence: 99%

“…Specimen collection and patient population. The study population has already been described elsewhere (18). Briefly, formalin-fixed, paraffin-embedded breast cancer tissues from 554 consecutive patients with invasive breast carcinoma were used.…”

Section: Methodsmentioning

confidence: 99%

“…TMA construction. TMAs were constructed as previously described (18). Briefly, for the 554 consecutive breast cancer specimens, the most representative tissue block from each case was selected by the pathologist for HER2 assessment by IHC and FISH.…”

Section: Methodsmentioning

confidence: 99%

“…Cytoplasmic staining was ignored and only invasive tumor was scored. Fluorescent signals were evaluated as previously described (18). Briefly, fluorescent signals were evaluated with an epifluorescence microscope (Axio Imager M1; Zeiss, Göttingen, Germany).…”

Section: Methodsmentioning

confidence: 99%

See 4 more Smart Citations

Concordance of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Using Tissue Microarray in Breast Cancer

Furrer

Jacob

Caron

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 78%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Concordance of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Using Tissue Microarray in Breast Cancer

Furrer

Jacob

Caron

et al. 2017

View full text Add to dashboard Cite

show abstract

Elevated serum HER‐2 predicts poor prognosis in breast cancer and is correlated to ADAM10 expression

et al. 2019

View full text Add to dashboard Cite

Human epidermal growth factor receptor‐2 (HER‐2) overexpression in breast tumor tissues is associated with a poor prognosis but may benefit from treatment with trastuzumab. The extracellular domain (ECD) of HER‐2 can be measured in serum and which has been a new inspection item in clinical laboratory of several hospitals. However, whether serum HER‐2 ECD can be a marker of HER‐2 status in tumor tissues still confused clinicians. This study is a retrospective observation to explore the correlation between serum HER‐2 ECD shedding and tissue HER‐2 status in breast cancer patients. Meanwhile, we will further uncover the potential clinical significance of serum HER‐2 ECD detection. A total of 545 unselected breast cancer patients from Fudan University Shanghai Cancer Center were enrolled in this study. At primary diagnosis without any treatment, serum HER‐2 ECD was measured on ADVIA Centaur assay; meanwhile, tissue HER‐2 from core needle biopsy was tested through immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH). We showed that serum HER‐2 ECD concentration was related to tissue HER‐2 status. Nevertheless, 36.9% of patients with tissue HER‐2 overexpression had low levels of HER‐2 ECD shedding (<15 ng/mL) in serum. Here, we demonstrated that HER‐2 ECD shedding was also associated with protein expression and alpha‐secretase activity of a disintegrin and metalloproteinase 10 (ADAM10) using tumor tissues and cell lines. Progression‐free survival (PFS) data from breast cancer patients in TNM phase II and III with tissue HER‐2 IHC 3+ were analyzed using Kaplan‐Meier plotter. The patients with serum HER‐2 ECD above 15 ng/mL had lower progression‐free survival than those with serum HER‐2 ECD <15 ng/mL. Thus, serum HER‐2 ECD could be a biomarker to identify the subgroup of poorer outcome among HER‐2 overexpression breast cancer patients. Inhibition of ADAM10 activity may have potential therapeutic benefit for this most aggressive tumor subgroup.

show abstract

Re-evaluation of HER2 status in 606 breast cancers—gene protein assay on tissue microarrays versus routine pathological assessment

et al. 2020

View full text Add to dashboard Cite

Human epidermal growth factor receptor 2 (HER2) status in breast cancer is routinely determined through immunohistochemistry (IHC) and/or in situ hybridisation (ISH) performed on whole tissue sections (WS). The purpose was to evaluate whether a gene protein assay (GPA) combining IHC with ISH, performed on breast cancer tissue microarray (TMA), is suitable for largescale retrospective HER2 status evaluation. TMAs from 606 tumours from a Swedish population-based cohort (2005-2012) were stained with GPA. GPA IHC on TMA yielded weaker staining than IHC on WS during routine pathological assessment (86.0% agreement). However, final HER2 status agreement between GPA on TMA and WS based on both IHC and ISH was 97.7%. Only 14 tumours were discordant and one tumour with IHC score 1+ on both TMA and WS was HER2 amplified on TMA. In conclusion, GPA on TMA is suitable for large-scale retrospective evaluation of HER2 status.

show abstract

Tissue Microarray Is a Reliable Tool for the Evaluation of HER2 Amplification in Breast Cancer

Cited by 10 publications

References 26 publications

Concordance of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Using Tissue Microarray in Breast Cancer

Concordance of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Using Tissue Microarray in Breast Cancer

Elevated serum HER‐2 predicts poor prognosis in breast cancer and is correlated to ADAM10 expression

Re-evaluation of HER2 status in 606 breast cancers—gene protein assay on tissue microarrays versus routine pathological assessment

Contact Info

Product

Resources

About